Compare Gemini Space Station Inc (GEMI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Novo Nordisk A/S — how do they compare? Gemini Space Station Inc trades at $4.4 (market cap $579.55M), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 285.2× Gemini Space Station Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 14 Days and Novo Nordisk A/S for 116 Days on average.
| GEMI | NVO | |
|---|---|---|
Market Cap | $579.55M | $165.31B |
Volume | 1,882,406 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $23.45 | $63.98 |
52-Week Low | $3.54 | $35.29 |
Typical Hold Time | 14 Days | 116 Days |
Enterprise Value | $558.57M | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GEMI trades at $4.47, down 0.45% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported Q2 2026 revenue growth of 37% year-over-year to $207 million but continues to post significant losses with a net income margin of -250.13%. Recent news highlights expansion into commission-free stock trading and prediction markets, though the stock faces class action lawsuits and mixed analyst sentiment.
The outlook remains challenging with persistent losses and negative cash flow from operations, though analyst consensus suggests 17% upside to the $5.25 price target. Key risks include ongoing litigation, competitive pressures in financial services, and the company's ability to achieve profitability amid high operating costs.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
